A recent collaboration between Onconova Therapeutics and Mission will utilize the Mission Bio TapestriⓇ Platform to conduct targeted single-cell DNA analysis for the study of Onconova's novel cancer therapy, Rigosertib. We spoke with Darrin Crisitello, CCO of Mission Bio, to learn more.
First-of-Its-Kind Lipidomics Excellence Award Acknowledges Forward-thinking in a Rapidly Growing FieldIndustry Insight
Technology Networks recently visited Dresden, Germany, for Lipotype's Lipid Excellence Award press talk, where we gained insights into the past, present and future of lipidomics research.Read More
To learn how Campylobacter hides from the body’s immune system, why some people are more susceptible than others, and the potential role that carbohydrate-based diagnostics could play in the fight against the bacterium, we spoke to Professor Rob Field, Co-founder of Iceni Diagnostics.Read More
Recent developments in MS technology have enabled a fourth dimension of analysis: ion mobility separation. The term "4D proteomics" has been created to describe analysis that incorporates all four dimensions. We interviewed two researchers at the forefront of the proteomics field to learn more about how 4D proteomics approaches are enhancing their research.
Technology Networks recently spoke with Professor Jürgen Cox to learn more about the computational software tools his laboratory are developing, and how 4D proteomics workflows enhance research in clinical proteomics.Read More
Digitization is a trend threading many disciplines, and lateral flow is no exception. Here, we share insights from Dave Taylor, co-founder and chief operating officer of Bond Digital Health, a UK-based life sciences company that develops app and cloud technology solutions for lateral flow diagnostics.Read More
We recently spoke with Paul Wotton, Ph.D., CEO at Obsidian Therapeutics, to gain his insights on the genetically engineered cell-therapy research area, and to learn how Obsidian Therapeutics' cytoDRiVE platform can increases the specificity and safety of such therapies.Read More
Fluid Imaging Technologies and the University of Colorado Boulder have recently entered an exclusive research agreement to determine whether the University’s artificial intelligence software can identify bloodborne bacteria. We spoke with Kent Peterson, CEO, Fluid Imaging Technologies, to learn more about the collaboration, the technologies involved, and how they could impact patients.Read More
We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.Read More